Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential for ex vivo delivery.

Journal Article (Journal Article;Review)

Organ shortages and an expanding waitlist have led to increased utilization of marginal organs. All donor organs are subject to varying degrees of IRI during the transplant process. Extended criteria organs, including those from older donors and organs donated after circulatory death are especially vulnerable to ischemia-reperfusion injury (IRI). Involvement of the complement cascade in mediating IRI has been studied extensively. Complement plays a vital role in the propagation of IRI and subsequent recruitment of the adaptive immune elements. Complement inhibition at various points of the pathway has been shown to mitigate IRI and minimize future immune-mediated injury in preclinical models. The recent introduction of ex vivo machine perfusion platforms provides an ideal window for therapeutic interventions. Here we review the role of complement in IRI by organ system and highlight potential therapeutic targets for intervention during ex vivo machine preservation of donor organs.

Full Text

Duke Authors

Cited Authors

  • Delaura, IF; Gao, Q; Anwar, IJ; Abraham, N; Kahan, R; Hartwig, MG; Barbas, AS

Published Date

  • 2022

Published In

Volume / Issue

  • 13 /

Start / End Page

  • 1000172 -

PubMed ID

  • 36341433

Pubmed Central ID

  • PMC9626853

Electronic International Standard Serial Number (EISSN)

  • 1664-3224

Digital Object Identifier (DOI)

  • 10.3389/fimmu.2022.1000172


  • eng

Conference Location

  • Switzerland